130 related articles for article (PubMed ID: 37902955)
1. Prognostic impact of lymph node involvement and loss of heterozygosity of 1p or 16q in stage III favorable histology Wilms tumor: A report from Children's Oncology Group Studies AREN03B2 and AREN0532.
Evageliou N; Renfro LA; Geller J; Perlman E; Kalapurakal J; Paulino A; Dix D; Eklund MJ; Murphy AJ; Romao RLP; Ehrlich PF; Varela CR; Vallance K; Fernandez CV; Dome JS; Mullen EA
Cancer; 2024 Mar; 130(5):792-802. PubMed ID: 37902955
[TBL] [Abstract][Full Text] [Related]
2. Outcome and Prognostic Factors in Stage III Favorable-Histology Wilms Tumor: A Report From the Children's Oncology Group Study AREN0532.
Fernandez CV; Mullen EA; Chi YY; Ehrlich PF; Perlman EJ; Kalapurakal JA; Khanna G; Paulino AC; Hamilton TE; Gow KW; Tochner Z; Hoffer FA; Withycombe JS; Shamberger RC; Kim Y; Geller JI; Anderson JR; Grundy PE; Dome JS
J Clin Oncol; 2018 Jan; 36(3):254-261. PubMed ID: 29211618
[TBL] [Abstract][Full Text] [Related]
3. Augmentation of Therapy for Combined Loss of Heterozygosity 1p and 16q in Favorable Histology Wilms Tumor: A Children's Oncology Group AREN0532 and AREN0533 Study Report.
Dix DB; Fernandez CV; Chi YY; Mullen EA; Geller JI; Gratias EJ; Khanna G; Kalapurakal JA; Perlman EJ; Seibel NL; Ehrlich PF; Malogolowkin M; Anderson J; Gastier-Foster J; Shamberger RC; Kim Y; Grundy PE; Dome JS;
J Clin Oncol; 2019 Oct; 37(30):2769-2777. PubMed ID: 31449468
[TBL] [Abstract][Full Text] [Related]
4. Loss of Heterozygosity at Chromosome 16q Is a Negative Prognostic Factor in Korean Pediatric Patients with Favorable Histology Wilms Tumor: A Report of the Korean Pediatric Hematology Oncology Group (K-PHOG).
Park JE; Noh OK; Lee Y; Choi HS; Han JW; Hahn SM; Lyu CJ; Lee JW; Yoo KH; Koo HH; Jeong SY; Sung KW
Cancer Res Treat; 2020 Apr; 52(2):438-445. PubMed ID: 31505910
[TBL] [Abstract][Full Text] [Related]
5. Loss of heterozygosity for chromosomes 1p and 16q is an adverse prognostic factor in favorable-histology Wilms tumor: a report from the National Wilms Tumor Study Group.
Grundy PE; Breslow NE; Li S; Perlman E; Beckwith JB; Ritchey ML; Shamberger RC; Haase GM; D'Angio GJ; Donaldson M; Coppes MJ; Malogolowkin M; Shearer P; Thomas PR; Macklis R; Tomlinson G; Huff V; Green DM;
J Clin Oncol; 2005 Oct; 23(29):7312-21. PubMed ID: 16129848
[TBL] [Abstract][Full Text] [Related]
6. [Correlation of 1p/16q loss of heterozygosity and 1p gain with clinicopathological characteristics and prognosis in Wilms tumor].
Jia C; Yao XF; Zhang M; Guan XX; Wang JW; Song HC; He LJ
Zhonghua Bing Li Xue Za Zhi; 2024 Mar; 53(3):257-263. PubMed ID: 38433053
[No Abstract] [Full Text] [Related]
7. Profiling Loss of Heterozygosity Patterns in a Cohort of Favorable Histology Nephroblastoma Egyptian Patients: What is Consistent With the Rest of the World.
Fawzy M; Bahanassy A; Samir A; Hafez H
Pediatr Hematol Oncol; 2015; 32(8):548-56. PubMed ID: 26390800
[TBL] [Abstract][Full Text] [Related]
8. 16q heterozygosity loss in Wilms' tumour in children and its clinical importance.
Skotnicka-Klonowicz G; Rieske P; Bartkowiak J; Szymik-Kantorowicz S; Daszkiewicz P; Debiec-Rychter M
Eur J Surg Oncol; 2000 Feb; 26(1):61-6. PubMed ID: 10718182
[TBL] [Abstract][Full Text] [Related]
9. Allele loss at 16q defines poorer prognosis Wilms tumour irrespective of treatment approach in the UKW1-3 clinical trials: a Children's Cancer and Leukaemia Group (CCLG) Study.
Messahel B; Williams R; Ridolfi A; A'hern R; Warren W; Tinworth L; Hobson R; Al-Saadi R; Whyman G; Brundler MA; Kelsey A; Sebire N; Jones C; Vujanic G; Pritchard-Jones K;
Eur J Cancer; 2009 Mar; 45(5):819-26. PubMed ID: 19231157
[TBL] [Abstract][Full Text] [Related]
10. Loss of heterozygosity for chromosomes 16q and 1p in Wilms' tumors predicts an adverse outcome.
Grundy PE; Telzerow PE; Breslow N; Moksness J; Huff V; Paterson MC
Cancer Res; 1994 May; 54(9):2331-3. PubMed ID: 8162576
[TBL] [Abstract][Full Text] [Related]
11. Treatment of Stage IV Favorable Histology Wilms Tumor With Lung Metastases: A Report From the Children's Oncology Group AREN0533 Study.
Dix DB; Seibel NL; Chi YY; Khanna G; Gratias E; Anderson JR; Mullen EA; Geller JI; Kalapurakal JA; Paulino AC; Perlman EJ; Ehrlich PF; Malogolowkin M; Gastier-Foster JM; Wagner E; Grundy PE; Fernandez CV; Dome JS
J Clin Oncol; 2018 Jun; 36(16):1564-1570. PubMed ID: 29659330
[TBL] [Abstract][Full Text] [Related]
12. Gain of 1q is associated with inferior event-free and overall survival in patients with favorable histology Wilms tumor: a report from the Children's Oncology Group.
Gratias EJ; Jennings LJ; Anderson JR; Dome JS; Grundy P; Perlman EJ
Cancer; 2013 Nov; 119(21):3887-94. PubMed ID: 23983061
[TBL] [Abstract][Full Text] [Related]
13. Patterns of lymph node sampling and the impact of lymph node density in favorable histology Wilms tumor: An analysis of the national cancer database.
Saltzman AF; Carrasco A; Amini A; Aldrink JH; Dasgupta R; Gow KW; Glick RD; Ehrlich PF; Cost NG
J Pediatr Urol; 2018 Apr; 14(2):161.e1-161.e8. PubMed ID: 29133167
[TBL] [Abstract][Full Text] [Related]
14. Clinicopathologic correlates of loss of heterozygosity in Wilm's tumor: a preliminary analysis.
Grundy P; Telzerow P; Moksness J; Breslow NE
Med Pediatr Oncol; 1996 Nov; 27(5):429-33. PubMed ID: 8926924
[TBL] [Abstract][Full Text] [Related]
15. Treatment of children with favorable histology Wilms tumor with extrapulmonary metastases: A report from the COG studies AREN0533 and AREN03B2 and NWTSG study NWTS-5.
Benedetti DJ; Varela CR; Renfro LA; Tornwall B; Dix DB; Ehrlich PF; Glick RD; Kalapurakal J; Perlman E; Gratias E; Seibel NL; Geller JI; Khanna G; Malogolowkin M; Grundy P; Fernandez CV; Dome JS; Mullen EA
Cancer; 2024 Mar; 130(6):947-961. PubMed ID: 37933882
[TBL] [Abstract][Full Text] [Related]
16. Loss of heterozygosity analysis at different chromosome regions in Wilms tumor confirms 1p allelic loss as a marker of worse prognosis: a study from the Italian Association of Pediatric Hematology and Oncology.
Spreafico F; Gamba B; Mariani L; Collini P; D'Angelo P; Pession A; Di Cataldo A; Indolfi P; Nantron M; Terenziani M; Morosi C; Radice P; Perotti D;
J Urol; 2013 Jan; 189(1):260-6. PubMed ID: 23174227
[TBL] [Abstract][Full Text] [Related]
17. Clinical Outcome and Biological Predictors of Relapse After Nephrectomy Only for Very Low-risk Wilms Tumor: A Report From Children's Oncology Group AREN0532.
Fernandez CV; Perlman EJ; Mullen EA; Chi YY; Hamilton TE; Gow KW; Ferrer FA; Barnhart DC; Ehrlich PF; Khanna G; Kalapurakal JA; Bocking T; Huff V; Tian J; Geller JI; Grundy PE; Anderson JR; Dome JS; Shamberger RC
Ann Surg; 2017 Apr; 265(4):835-840. PubMed ID: 27811504
[TBL] [Abstract][Full Text] [Related]
18. Association of Chromosome 1q Gain With Inferior Survival in Favorable-Histology Wilms Tumor: A Report From the Children's Oncology Group.
Gratias EJ; Dome JS; Jennings LJ; Chi YY; Tian J; Anderson J; Grundy P; Mullen EA; Geller JI; Fernandez CV; Perlman EJ
J Clin Oncol; 2016 Sep; 34(26):3189-94. PubMed ID: 27400937
[TBL] [Abstract][Full Text] [Related]
19. Association between loss of heterozygosity of chromosome 16q and survival in Wilms' tumor: A meta-analysis.
Bu Q; He H; Fan D; Lyu J; Pan Z; You H
Pathol Res Pract; 2018 Nov; 214(11):1772-1777. PubMed ID: 30143352
[TBL] [Abstract][Full Text] [Related]
20. Genomic profiling maps loss of heterozygosity and defines the timing and stage dependence of epigenetic and genetic events in Wilms' tumors.
Yuan E; Li CM; Yamashiro DJ; Kandel J; Thaker H; Murty VV; Tycko B
Mol Cancer Res; 2005 Sep; 3(9):493-502. PubMed ID: 16179496
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
